Medical Xpress covered UB research which demonstrates that dexrazoxane, which is administered to pediatric cancer patients in order to curb the cardiotoxicity of a key chemotherapy drug, has no adverse impacts on these patients, even nearly 20 years later. “The longer term effects of dexrazoxane had not been previously established, due to the short time it has been in clinical practice since the late 1990s,” said
Steven E. Lipshultz, senior author on the paper and A. Conger Goodyear Professor and Chair of
Pediatrics in the Jacobs School. “This is why this paper is so important, because it examines, for the first time, these longer term effects of dexrazoxane.”